Johnson and Johnson (JNJ) Cotización

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato...

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Joaquin Duato, Chairman and...

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study PR Newswire SAN...

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options PR Newswire SAN DIEGO, Dec...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly...

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma PR Newswire SAN DIEGO, Dec. 8, 2024 100 percent of...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma PR...